# Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer

> **NCT07632079** · PHASE2 · RECRUITING · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 60 (estimated)

## Conditions studied

- Locally Advanced Esophageal or GE Junction Cancer

## Interventions

- **RADIATION:** Hypofractionation
- **DRUG:** carboplatin + paclitaxel (CP)

## Key facts

- **NCT ID:** NCT07632079
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-28
- **Primary completion:** 2028-04
- **Final completion:** 2028-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07632079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07632079, "Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07632079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*